Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948868 | 0.92 | LMNA (0.39) | LMNAKDM1AALDH1A1HRH3MAPT | |
| SCHEMBL1077472 | 0.74 | ALDH1A1 (0.36) | LMNAALDH1A1HRH3MAPTCYP1A2 | |
| SCHEMBL933173 | 0.73 | CYP2D6 (0.41) | LMNAALDH1A1HRH3KDM4ESMN1; SMN2 | |
| SCHEMBL948263 | 0.73 | POLB (0.41) | LMNAKDM4EHPGD | |
| SCHEMBL950527 | 0.71 | ALDH1A1 (0.37) | GRM4LMNAALDH1A1GAAHRH3 | |
| SCHEMBL950462 | 0.71 | GRM4 (0.39) | GRM4LMNAKDM1AGAAHRH3 | |
| SCHEMBL6653067 | 0.70 | CYP3A4 (0.47) | GRM4LMNAALDH1A1GAAPKM | |
| SCHEMBL935029 | 0.69 | L3MBTL1 (0.48) | LMNAALDH1A1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL2067731 | 0.69 | — | — | |
| SCHEMBL18788938 | 0.69 | ALDH1A1 (0.35) | GRM4LMNAALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072890-B1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3072890-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI Pharma, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-8486939-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2532659-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | Pathway Therapeutics, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | TYMP, TYMS, CCNI | GRM4 4130/4885LMNA 3095/4885KDM1A 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.